MMIT Reality Check on Growth Hormone Deficiency (Jan 2020)

According to our recent payer coverage analysis for growth hormone deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for growth hormone deficiency treatments shows that under the pharmacy benefit, more than 63% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: As more growth hormone products become available, payers have even more tactics available to them to manage this specialty class. In particular, payers can manage their unit costs for these therapies by contracting with manufacturers to prefer products.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/12/wordpress-featured-image-reality-check-ovarian-cancer.jpg
December 3

MMIT Reality Check on Ovarian Cancer

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_Diabetes.jpg
November 24

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/wordpress-featured-image-reality-check-colorectal-cancer.jpg
November 19

MMIT Reality Check on Colorectal Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today